Investing in ImmuCell Corporation (ICCC)  ➔  Intrinsic value

Prev. close$9.69 
ModelValueUpside
Chepakovich$1.03-89%
Graham-Dodd$3.18-67%
Graham$0.00-100%
Previous Close$9.69  
Valuation MethodValuePotential 
Chepakovich Model$1.03-89%recalculate
Graham-Dodd$3.18-67%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.